A field-by-field walkthrough of a research peptide COA: identity, purity, mass, lot, stability, and the document trail behind a released lot. Written for procurement, lab managers, and research-program leads. Research use only.
By PeptideDistro Editorial · Published 2026-04-27 · ~7 minute read
A certificate of analysis is the single-page lot-release document that travels with a research peptide from the manufacturer or distributor to the buyer. For research-grade catalog peptides — the kind procurement teams source for in vitro studies, assay development, screening libraries, and analytical reference work — the COA functions as the formal record that the material in a particular vial matches what the catalog page describes. The COA is not a pharmacopeial release document, not a clinical batch record, and not a substitute for a research lab’s own incoming-material verification. It is, however, the source of truth for the seven or eight fields a procurement reviewer should be checking before a lot is accepted into inventory.
A research-grade COA differs from a pharmaceutical COA in three ways worth keeping in mind. First, it does not certify GMP manufacturing, sterility, pyrogen-free status, or human-use suitability unless those properties are explicitly stated and substantiated by the underlying analytical record. Second, it documents identity and purity rather than potency in pharmacological units; downstream activity work is the buyer’s responsibility under the relevant institutional protocols. Third, it describes a lot of research material — meaning the buyer accepts the document as a research-workflow input, not as labeling for a finished drug, supplement, or cosmetic. Section anchors below match the typical block order on a PeptideDistro.com COA, and the same field set is covered in our COA & document library and quality assurance process.
The top of a COA establishes who issued the record and which lot the record covers. At minimum the header should list the issuing entity (manufacturer or distributor of record), the document title (“Certificate of Analysis”), the catalog or part designation for the compound, and the lot or batch number that uniquely identifies the manufactured material. Document numbers, revision codes, and issue dates appear here as well; they let a procurement reviewer confirm that the COA in hand is the current version for a given lot, not a stale revision. A reviewer should match the lot number on the COA against the lot label on the vial or shipping carton — a mismatch is reason to halt acceptance until the issuing desk reconciles the document trail.
Procurement teams sometimes overlook that the issuing entity matters as much as the lot identifier. A COA produced by a distributor that simply repackages another lab’s output should clearly disclose the underlying manufacturing source or, at minimum, attest to the analytical record it relies on. PeptideDistro.com COAs identify the issuing reviewer and tie the document to the buyer-account record so that audit trails remain continuous after release.
Below the header, the identity block names the peptide, its amino-acid sequence, and any modifications (acetylation, amidation, PEGylation, fatty-acid conjugation, lactam bridges, D-amino acids, fluorophore conjugates, and so on). Sequence is shown using either single-letter or three-letter amino-acid notation, with N- and C-terminal modifications explicitly called out (for example, Ac- for N-terminal acetyl or -NH2 for C-terminal amide). For known reference peptides the sequence on the COA should match the public reference — typically a UniProt accession, PubChem CID, or peer-reviewed publication. A sequence mismatch between the COA and the catalog page is a stop-the-line issue.
The identity block is also where catalog cross-references should appear. PubChem CID and CAS number, where assigned, give the procurement reviewer a stable external identifier to verify the molecule against. UniProt accessions are useful for sequence-derived peptides such as fragments of insulin-like growth factor 1 or vasoactive intestinal peptide. The identity block should not contain dosage, indication, or therapeutic-context language; a research-peptide COA treats the molecule as a defined chemical entity and leaves use-case framing to the buyer.
The appearance line documents what the material looks like on receipt: lyophilized white powder, off-white powder, fluffy lyophile, glassy solid, viscous solution, and so on. Reasonable variations exist across peptides, but a deviation from the catalog-stated form is a flag. Water content (Karl Fischer or thermogravimetric analysis), residual organic-solvent indicators (typically acetonitrile from RP-HPLC purification), and counter-ion identity (acetate, trifluoroacetate, hydrochloride) are reported here when relevant. Counter-ion content matters for mass-balance accounting: a peptide reported as 95% pure may carry an additional 5–15% mass as counter-ion and water that the gross fill weight does not separate from the active peptide.
The purity block reports the result of a reverse-phase HPLC analysis against the lot-release threshold. Catalog peptides commonly carry a 95% or 98% threshold; many research-grade lots clear >98% purity. The COA should list the column chemistry (typically C18), the gradient or isocratic conditions, the detection wavelength (commonly 220 nm for peptide bond absorbance), and the calculated purity expressed as area percent. The supporting chromatogram, even if not printed on the COA itself, should be available on request through the issuing desk and is delivered as part of the batch documentation packet at PeptideDistro.com.
A purity number alone is not sufficient. The reviewer should confirm that the chromatogram shows a single dominant peak at the expected retention behavior, with no late-eluting hydrophobic impurities, no shoulder peaks suggestive of deletion or insertion sequences, and integration baselines that look reasonable. Where impurity peaks are present, the COA or supporting record should describe them. United States Pharmacopeia general chapter <621> on chromatography (USP, 2024) and the FDA’s Guidance for Industry: ANDAs: Impurities in Drug Substances (FDA, 2018) outline relevant analytical principles even for research-grade workflows.
The mass spectrometry block confirms identity by reporting the observed mass of the released material against the expected mass for the listed sequence and modifications. Common methods are electrospray ionization mass spectrometry (ESI-MS) and matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF). The COA should state the observed mass (monoisotopic or average, with the choice indicated), the expected mass calculated from the sequence, and the absolute or relative deviation. A deviation that exceeds the instrument’s established tolerance for the relevant mass range is reason to question the identity result.
For glycosylated, conjugated, or PEGylated peptides the expected-mass calculation must include the modifying group’s contribution; PEG-conjugated peptides additionally show a characteristic distribution of charge states or repeat-unit masses, and the COA should note which signal was used to call identity. The supporting MS spectrum is not always printed on the COA; PeptideDistro.com routes it on request as part of the batch documentation packet.
The lot block carries the information that ties analytical data to a specific manufactured batch: lot number, manufacture date, expiration date or stated stability window, and the storage conditions used to derive the stability claim. Expiration and stability windows for lyophilized peptides vary widely depending on sequence; reactive residues such as cysteine, methionine, and N-terminal glutamine affect stability. The COA should reference the storage conditions (typically −20 °C protected from light for lyophilized material) under which the stability window applies, and it should note that reconstituted material has its own, typically much shorter, stability profile.
Audit trails depend on the lot block being clean. Procurement teams should record the lot number, manufacture date, and expiration in inventory at receipt, alongside the COA reference, so that downstream batch-record review can reach back to the source document without ambiguity.
The last block on a research-peptide COA is the release attestation: the issuing reviewer’s name, the release date, and the research-use-only statement. This block converts the COA from a data sheet into a release document. Reviewers should treat the absence of an issuing-reviewer name or release date as a defect; both are required for an audit-traceable record.
The RUO statement explicitly excludes human and veterinary consumption, therapeutic claims, and downstream resale as drugs, supplements, or cosmetics. Procurement reviewers in regulated environments should confirm that the RUO statement aligns with the institutional procurement policy and that the use case planned for the material falls within the “research” envelope as defined locally.
Continue reading: HPLC and mass spectrometry for research peptides walks through the analytical methods that produce the data on the COA. The COA & document library documents how lot-specific records are released, and quality assurance covers the supplier-qualification, identity, purity, and lot-release process behind every record.
No. A research-peptide COA documents identity and purity for in vitro and laboratory research workflows. It is not a release document for a drug product, does not assert sterility or pyrogen-free status unless explicitly stated, and is not intended to support human or veterinary administration.
Catalog peptides commonly carry a 95% or 98% lot-release threshold by HPLC, with research-grade material frequently above 98%. The acceptable threshold depends on the downstream research workflow; the COA should state the threshold used for the specific lot.
Identity is confirmed by mass spectrometry — typically ESI-MS or MALDI-TOF — comparing observed mass against the expected mass for the listed sequence and modifications. Sequence and modification entries on the COA should match the catalog page for the compound.
This article is editorial reference for procurement and laboratory-workflow context. PeptideDistro.com does not provide medical advice, treatment claims, or dosage guidance. Lot-specific records are released to approved wholesale accounts only.